Regencell Bioscience's COVID-19 Candidate Shows Encouraging Action On Mild To Moderate Symptoms


Regencell Bioscience Holdings Limited RGC announced the results from the EARTH efficacy trial of its COVID-19 candidate.

  • RGC-COV19 (Regencell Bioscience (RGCA-CV01) liquid formulation) is an oral TCM candidate. 
  • Out of the 37 COVID-19 patients, 36 had all symptoms eliminated, save for Sensory Dysfunction & occasional cough, within the 6-day treatment period. 
  • The trial that after taking RGC-COV19TM, 97.3% of the patients had their mild to moderate COVID-19 symptoms eliminated, save for Sensory Dysfunction & occasional cough, within the 6-day treatment period
  • 15 out of the 36 patients experienced Sensory Dysfunction before receiving treatment. Among those 15 patients, 5 recovered their sensory functions, while the remaining 10 showed improvements at the end of the 6-day treatment period.
  • 31 out of 37 COVID-19 patients reported the elimination of one or more symptoms after taking 1 full dose of RGC-COV19.
  • The three non-vaccinated patients took an average of approximately 2.3 days for symptoms to be eliminated. 
  • The three partially vaccinated patients took an average of approximately 3.3 days for all symptoms to be eliminated, save for Sensory Dysfunction. 
  • No adverse side effects were observed, and there were no worsening of symptoms during and after consuming RGC-COV19.
  • At the end of the EARTH efficacy trial, none of the patients was hospitalized, and there was no death. 
  • Price Action: RGC shares are up 5.29% at $36.80 during the market session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareSmall CapMoversTrading IdeasGeneralBriefsCOVID-19 Coronavirus
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!